RESUMO
Porcine Circovirus type 2 (PCV2) associated disease is one of the most economically important swine diseases worldwide. Vaccines reduce PCV2 disease by inducing humoral immunity (neutralizing antibodies) and cell-mediated immunity (CMI) but may be improved by optimizing the immune response they induce. This study evaluated immune responses to a trivalent inactivated Porcine Circovirus (PCV) Type 1-Type 2a chimera (cPCV2a), cPCV2b and Mycoplasma hyopneumoniae (MH) (an experimental serial of Fostera® Gold PCV MH, also marketed as Circomax® Myco) vaccine or a bivalent recombinant PCV2a baculovirus expressed ORF2 capsid plus MH vaccine (Circumvent® PCV-M G2). Treatment Groups (T) received two doses of placebo (T01), one full or two split doses of the trivalent vaccine (T02, T03) or two split doses of the bivalent vaccine (T04) where two doses were given, there was a three-week period between administrations. All pigs were challenged with a virulent field isolate of PCV2d. CMI was measured as PCV2-specific IFN-γ secreting cells in blood and lymph node. Humoral immunity was measured as PCV2 antibodies. Vaccine efficacy was determined as viremia and fecal shedding of virus. There was a robust antibody response in T02 and T04 post the second vaccination and all vaccinated groups post challenge. There was a robust PCV2-specific IFN-γ response following the 1st dose in T02 and T03 and after the second dose in T02. T04 induced a low but detectable PCV2-specific IFN-γ response only after the 2nd dose. Among lymph node cells (study day 52), there was a significantly higher PCV2-specific, IFN-γ response to replicase and PCV2d capsid peptides in T01, consistent with active viral replication in non-vaccinated pigs. The trivalent chimeric vaccine induced robust CMI and protective efficacy, following a one dose regimen or splitting the dose into two vaccine administrations.
Assuntos
Infecções por Circoviridae , Circovirus , Doenças dos Suínos , Vacinas Virais , Animais , Anticorpos Antivirais , Infecções por Circoviridae/prevenção & controle , Infecções por Circoviridae/veterinária , Imunidade Humoral , Suínos , Doenças dos Suínos/prevenção & controle , VacinaçãoRESUMO
Objective The role of anticoagulation (AC) in the management of otogenic cerebral venous sinus thrombosis (OCVST) remains controversial. Our study aims to better define when AC is used in OCVST. Methods MEDLINE, EMBASE, and The Cochrane Library were searched from inception to February 14, 2019 for English and English-translated articles. References cited in publications meeting search criteria were searched. Titles and abstracts were screened and identified in the literature search, assessing baseline risk of bias on extracted data with the methodological index for nonrandomized studies (MINORS) scale. Random effects meta-regression followed by random forest machine learning analysis across 16 moderator variables between AC and nonanticoagulated (NAC) cohorts was conducted. Results A total of 92% of treated patients were free of neurologic symptoms at the last follow-up (mean 29.64 months). Four percent of AC and 14% of NAC patients remained symptomatic (mean 18.72 and 47.10 months). 3.5% of AC patients experienced postoperative wound hematomas. AC and NAC recanalization rates were 81% (34/42) and 63% (five-eights), respectively. OCVST was correlated with cholesteatoma and intracranial abscess. Among the analyzed covariates, intracranial abscess was most predictive of AC and cholesteatoma was most predictive of NAC. Comorbid intracranial abscess and cholesteatoma were predictive of AC. Conclusion The present study is the first to utilize machine learning algorithms in approaching OCVST. Our findings support the therapeutic use of AC in the management of OCVST when complicated by thrombophilia, intracranial abscess, and cholesteatoma. Patients with intracranial abscess and cholesteatoma may benefit from AC and surgery. Patients with cholesteatoma can be managed with NAC and surgery.
RESUMO
OBJECTIVE: To review the demographics, treatment modalities, and survival of children with vestibular schwannomas. STUDY DESIGN: Analysis using the Surveillance, Epidemiology, and End Results (SEER) database. SUBJECTS AND METHODS: Pediatric patients from birth to 18 years in the SEER database were included from 2004 to 2014 based on a diagnosis of vestibular schwannoma using the primary site International Classification of Diseases (ICD) O-3 code of C72.4: acoustic nerve and the ICD O-3 histology codes of 9540/1: neurofibromatosis, Not Otherwise Specified (NOS); 9560/0: neurilemoma, NOS; or 9570/0: neuroma, NOS. RESULTS: One hundred forty-eight pediatric vestibular schwannomas (VSs) cases were identified. The mean age at diagnosis was 13.9 years (range, 4.0-18.0). Eighty-five (57.4%) patients were women. Seventy-seven (52.0%) patients had isolated unilateral VSs while 71 (48.0%) patients had either bilateral VSs or unilateral VSs with other brain, spinal cord, or cranial nerve tumors. Eighty two (55.4%) patients received surgical resection only, 45 (30.4%) received no treatment, 6 (4.1%) received radiation only, and 12 (8.1%) received surgery and radiation. The median tumor size for patients who received no treatment was 9.5âmm (interquartile range [IQR]: 8.0) compared with 33.5âmm (IQR: 23.0) for patients who received surgical care and 41.0âmm (IQR: 1.5) for patients who received both surgery and radiation (pâ<â0.001). The 5-year overall survival rate was 97%. CONCLUSION: Pediatric VSs tend to be diagnosed in adolescence. No men or women predominance was appreciated. Treatment varied according to tumor size. Survival rates for children with vestibular schwannomas are excellent. These data may assist healthcare providers when counseling children with vestibular schwannomas and their families.
Assuntos
Neuroma Acústico , Adolescente , Criança , Pré-Escolar , Feminino , Humanos , Masculino , Neuroma Acústico/epidemiologia , Neuroma Acústico/patologia , Neuroma Acústico/terapia , Programa de SEERRESUMO
Rapid calibration of liquid crystal variable retarder (LCVR) devices is critical for successful clinical implementation of a LC-based Mueller matrix imaging system being developed for noninvasisve skin cancer detection. For multispectral implementation of such a system, the effect of wavelength (lambda), temperature (T), and voltage (V) on the retardance (delta) required to generate each desired polarization state needs to be clearly understood. Calibration involves quantifying this interdependence such that for a given set of system input variables (lambda,T), the appropriate voltage is applied across a LC cell to generate a particular retardance. This paper presents findings that elucidate the dependence of voltage, for a set retardance, on the aforementioned variables for a nematic LC cell: approximately 253 mV/100 nm lambda-dependence and approximately 10 mV/ degrees CT-dependence. Additionally, an empirically derived model is presented that enables initial voltage calibration of retardance for any desired input wavelength within the calibration range of 460-905 nm.